Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. Combining rituximab with combination chemotherapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination
chemotherapy in treating patients who have previously untreated non-Hodgkin's lymphoma.